Key result
Public healthcare in SLE is linked to greater 10-year damage accrual than private care, with similar mortality.
Cohort (n=301)
Yes
Answers are grounded in this paper and cite their sources.
Recent studies on systemic lupus erythematosus (SLE) have reported more favorable outcomes thanks to better knowledge of the disease, more expert management of it, and rational use of treatments. In this study we identified 301 SLE patients, seen between 1988 and 2019. Two hundred and twenty eight patients were treated in the public health system and 73 in private practice. In comparing both groups, we discovered that patients in the public health system were youn-ger at first consultation and at SLE onset and that the mean duration of their disease prior to first consultation was shorter in a statistically significant way. Also, they showed more frequence of leucopenia, Sm antibody, renal involvement and received I.V. corticosteroids. Patients treated in the public system of health showed more accrual damage over the 10 first years of the disease than patients seen in the private system of health, but death in both groups was similar. Patients from both public and private groups were attended by medical specialist practices who made close follow-ups.
No takes yet. Share an insight, caveat, or question.
Calvo et al. (2020) conducted a cohort in Systemic lupus erythematosus (SLE) (n=301). Treatment in the public health system vs. Treatment in private practice was evaluated on Accrual damage and death over the first 10 years of disease. Treatment in the public health system was associated with more accrual damage over the first 10 years of SLE compared to private practice, although mortality was similar between both groups.
Synapse has enriched 10 related papers. Consider them for comparative context: